Demographic comparison among subject groups
. | Control . | SLE . | T1D . |
|---|---|---|---|
| Number of subjects | 26 | 24 | 25 |
| Average age (yr) | 33.8 (22–52) | 37.3 (21–55) | 38.5 (19–69) |
| Female (%)a | 0.88 | 0.88 | 0.56 |
| Caucasian (%)a | 0.58 | 0.29 | 0.92 |
| African-American (%) | 0.27 | 0.42 | 0.04 |
| Other (%) | 0.15 | 0.29 | 0.04 |
| Mean κ/λ ratio (CD19+) | 1.5 (1.1–2.3) | 1.8 (1–4) | 1.6 (0.8–2.4) |
| Mean B cell fraction (CD19+) | 0.11 (0.05–0.19) | 0.1 (0.01–0.2) | 0.1 (0.02–0.19) |
| Mean absolute B cell count (per μl)b | 221 ± 126 | 176 ± 163 | 190 ± 107 |
. | Control . | SLE . | T1D . |
|---|---|---|---|
| Number of subjects | 26 | 24 | 25 |
| Average age (yr) | 33.8 (22–52) | 37.3 (21–55) | 38.5 (19–69) |
| Female (%)a | 0.88 | 0.88 | 0.56 |
| Caucasian (%)a | 0.58 | 0.29 | 0.92 |
| African-American (%) | 0.27 | 0.42 | 0.04 |
| Other (%) | 0.15 | 0.29 | 0.04 |
| Mean κ/λ ratio (CD19+) | 1.5 (1.1–2.3) | 1.8 (1–4) | 1.6 (0.8–2.4) |
| Mean B cell fraction (CD19+) | 0.11 (0.05–0.19) | 0.1 (0.01–0.2) | 0.1 (0.02–0.19) |
| Mean absolute B cell count (per μl)b | 221 ± 126 | 176 ± 163 | 190 ± 107 |
Significant differences were found with respect to gender and race between the T1D and control groups (P < 0.05 and P < 0.01, respectively) as well as between the T1D and SLE groups (P < 0.05 and P < 0.001, respectively).
Absolute B cell counts were obtained by multiplying the WBC count (from the complete blood count) by the percentage of lymphocytes (from the electronic differential) and by the CD19+ fraction, and are listed as means ± SD. Absolute B cell counts represent the average of 25 control subjects, 23 SLE patients, and 24 T1D patients, respectively.